Table 2. Demographics, clinical characteristics, and prognostic biomarkers in patients with versus without BRAF, FBXW7, NRAS, and/or XPO1 mutations (n=499 ‡).

Patient/disease characteristic	BRAF, FBXW7, NRAS, and/or XPO1 mutation		P
	Yes % (n=73)	No % (n=426)
Aged >70 years	34	30	0.5
Male	78	71	0.2
Binet stage C *	36	31	0.4
Randomised arm chlorambucil	52	47	0.5
Non-response to treatment	21	21	1.0
≥ 2 lines of treatment	73	66	0.3
Unmutated IGHV genes (>98% homology) ‡	84	59	0.0002
β2 microglobulin ≥4 mg/L ‡	55	47	0.3
CD38 positive (cut-off 7%) ‡	78	61	0.02
Zap-70 positive (cut-off 10%) ‡	65	47	0.02
Trisomy 12 ‡	29	14	0.003
11q deletion ‡	24	20	0.5
Absence of 13q deletion ‡	62	37	0.0001
17p deletion ‡	8	5	0.5
ATM mutation	8	7	0.8
BIRC3 mutation	12	6	0.07
EGR2 mutation	1	3	0.5
KRAS mutation	15	4	0.0003
NOTCH1 mutation	21	11	0.02
SF3B1 mutation	15	26	0.05
TP53 mutation	15	9	0.09

^*Binet stage C disease was not significant because, while patients with these gene mutations were more likely than others to have anaemia (haemoglobin <100g/L; 33% vs. 18%; P=0.003), they were less likely to have thrombocytopenia (platelets <100x10⁹/L; 10% v. 21%; P=0.02).

^‡Eight variables had missing data, with the no. of cases ranging from 356 to 464.